7/103 sources · 3 publishersUpdated Nov 5, 15:22 UTC
Madrigal shares real‑world data showing high persistence and liver‑stiffness improvements with Rezdiffra
Madrigal Pharmaceuticals presented real‑world study results for its MASH drug Rezdiffra at the AASLD meeting. Between 37% and 55% of patients achieved at least a 25% reduction in liver stiffness after roughly one year, and 83% to 93% showed improvement or stabilization. Up to 72% of patients remained on therapy at 12 months, and safety was consistent with trial data.
Why it matters
The company’s press release notes that the data reinforce Rezdiffra’s effectiveness and may encourage broader clinical use. Analyst commentary says the real‑world results support treatment uptake, though no direct sales impact is quantified.
Key facts
- 1Up to 72% of patients remained on Rezdiffra at 12 months. stocktitan.net
- 2Between 37% and 55% of patients with paired measurements achieved at least a 25% improvement in liver stiffness after approximately one year. stocktitan.net
- 3Between 83% and 93% of patients experienced improvement or stabilization of liver stiffness. stocktitan.net
- 4Mean ALT decreased by 16.2 U/L at 12 months. stocktitan.net
- 5Mean liver stiffness decreased by 2.5 kPa at 12 months. stocktitan.net
- 6Mean LDL cholesterol decreased by 15.5 mg/dL at 12 months. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.